OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING
Oroxylin A is a potential inhibitory compound that could be applied to treat rheumatoid arthritis (RA). Rheumatoid arthritis is a chronic, systemic autoimmune disease that can lead to joint damage, deformity, and disability if not effectively treated. Current research utilizes network pharmacol...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Trường Đại học Vinh
2025-03-01
|
| Series: | Tạp chí Khoa học |
| Subjects: | |
| Online Access: | https://vujs.vn//api/view.aspx?cid=0793f0df-a326-4dc4-9c03-6cbdc25fcea9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155186297765888 |
|---|---|
| author | Nguyen Thi Thuy Tram, Cao Hoang Minh Chau, Ngu Thi Tra Giang, Phan Thi Thuy* |
| author_facet | Nguyen Thi Thuy Tram, Cao Hoang Minh Chau, Ngu Thi Tra Giang, Phan Thi Thuy* |
| author_sort | Nguyen Thi Thuy Tram, Cao Hoang Minh Chau, Ngu Thi Tra Giang, Phan Thi Thuy* |
| collection | DOAJ |
| description | Oroxylin A is a potential inhibitory compound that could be
applied to treat rheumatoid arthritis (RA). Rheumatoid
arthritis is a chronic, systemic autoimmune disease that can
lead to joint damage, deformity, and disability if not
effectively treated. Current research utilizes network
pharmacology and molecular docking methods to predict the
primary mechanism of action of oroxylin A against
rheumatoid arthritis. Through screening via protein-protein
interaction networks (PPI), 67 potential RA-related targets
have been identified, with EGFR, PTGS2, ESR1, MMP9, and
GSK3B potentially serving as central targets. KEGG pathway
analysis indicates that these 67 potential targets are associated
with pathways related to metabolism, pathways in cancer,
PI3K-Akt signalling pathway, Ras signalling pathway, and
microRNAs in cancer. Molecular docking has been applied to
determine the binding mode and affinity of oroxylin A with
these five central RA-related targets. These findings offer the
potential to inhibit relevant biological targets and provide a
basis for further research into the mechanism of oroxylin A
against RA. |
| format | Article |
| id | doaj-art-7f546d7da2c04b4b99e35ac23e27c3c2 |
| institution | OA Journals |
| issn | 1859-2228 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Trường Đại học Vinh |
| record_format | Article |
| series | Tạp chí Khoa học |
| spelling | doaj-art-7f546d7da2c04b4b99e35ac23e27c3c22025-08-20T02:25:01ZengTrường Đại học VinhTạp chí Khoa học1859-22282025-03-01541A12714010.56824/vujs.2024a125aOROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKINGNguyen Thi Thuy Tram, Cao Hoang Minh Chau, Ngu Thi Tra Giang, Phan Thi Thuy*0Department of Chemistry, College of Education, Vinh University, Nghe An, VietnamOroxylin A is a potential inhibitory compound that could be applied to treat rheumatoid arthritis (RA). Rheumatoid arthritis is a chronic, systemic autoimmune disease that can lead to joint damage, deformity, and disability if not effectively treated. Current research utilizes network pharmacology and molecular docking methods to predict the primary mechanism of action of oroxylin A against rheumatoid arthritis. Through screening via protein-protein interaction networks (PPI), 67 potential RA-related targets have been identified, with EGFR, PTGS2, ESR1, MMP9, and GSK3B potentially serving as central targets. KEGG pathway analysis indicates that these 67 potential targets are associated with pathways related to metabolism, pathways in cancer, PI3K-Akt signalling pathway, Ras signalling pathway, and microRNAs in cancer. Molecular docking has been applied to determine the binding mode and affinity of oroxylin A with these five central RA-related targets. These findings offer the potential to inhibit relevant biological targets and provide a basis for further research into the mechanism of oroxylin A against RA.https://vujs.vn//api/view.aspx?cid=0793f0df-a326-4dc4-9c03-6cbdc25fcea9oroxylin arheumatoid arthritisnetwork pharmacologymolecular docking |
| spellingShingle | Nguyen Thi Thuy Tram, Cao Hoang Minh Chau, Ngu Thi Tra Giang, Phan Thi Thuy* OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING Tạp chí Khoa học oroxylin a rheumatoid arthritis network pharmacology molecular docking |
| title | OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING |
| title_full | OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING |
| title_fullStr | OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING |
| title_full_unstemmed | OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING |
| title_short | OROXYLIN A, AS A POTENTIAL INHIBITOR OF RHEUMATOID ARTHRITIS: IN SILICO EXPERIMENT BASED ON NETWORK PHARMACOLOGY AND MOLECULAR DOCKING |
| title_sort | oroxylin a as a potential inhibitor of rheumatoid arthritis in silico experiment based on network pharmacology and molecular docking |
| topic | oroxylin a rheumatoid arthritis network pharmacology molecular docking |
| url | https://vujs.vn//api/view.aspx?cid=0793f0df-a326-4dc4-9c03-6cbdc25fcea9 |
| work_keys_str_mv | AT nguyenthithuytramcaohoangminhchaunguthitragiangphanthithuy oroxylinaasapotentialinhibitorofrheumatoidarthritisinsilicoexperimentbasedonnetworkpharmacologyandmoleculardocking |